Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Postoperative use of the chemopreventive vitamin K2 analog in patients with hepatocellular carcinoma.

Zhong JH, Mo XS, Xiang BD, Yuan WP, Jiang JF, Xie GS, Li LQ.

PLoS One. 2013;8(3):e58082. doi: 10.1371/journal.pone.0058082. Epub 2013 Mar 7.

2.

Adjuvant therapy options following curative treatment of hepatocellular carcinoma: a systematic review of randomized trials.

Zhong JH, Li H, Li LQ, You XM, Zhang Y, Zhao YN, Liu JY, Xiang BD, Wu GB.

Eur J Surg Oncol. 2012 Apr;38(4):286-95. doi: 10.1016/j.ejso.2012.01.006. Epub 2012 Jan 24. Review.

PMID:
22281155
3.

Role of vitamin K2 in preventing the recurrence of hepatocellular carcinoma after curative treatment: a meta-analysis of randomized controlled trials.

Riaz IB, Riaz H, Riaz T, Rahman S, Amir M, Badshah MB, Kazi AN.

BMC Gastroenterol. 2012 Nov 29;12:170. doi: 10.1186/1471-230X-12-170.

4.

Effect of vitamin K2 on the recurrence in patients with hepatocellular carcinoma.

Hotta N, Ayada M, Sato K, Ishikawa T, Okumura A, Matsumoto E, Ohashi T, Kakumu S.

Hepatogastroenterology. 2007 Oct-Nov;54(79):2073-7.

PMID:
18251162
5.

Vitamin analogues in chemoprevention of hepatocellular carcinoma after resection or ablation--a systematic review and meta-analysis.

Chu KJ, Lai EC, Yao XP, Zhang HW, Lau WY, Fu XH, Lu CD, Shi J, Cheng SQ.

Asian J Surg. 2010 Jul;33(3):120-6. doi: 10.1016/S1015-9584(10)60021-8. Review.

6.
7.

Effect of menatetrenone, a vitamin k2 analog, on recurrence of hepatocellular carcinoma after surgical resection: a prospective randomized controlled trial.

Ishizuka M, Kubota K, Shimoda M, Kita J, Kato M, Park KH, Shiraki T.

Anticancer Res. 2012 Dec;32(12):5415-20.

PMID:
23225445
8.

Carboxylic Derivatives of Vitamin K2 Inhibit Hepatocellular Carcinoma Cell Growth through Caspase/Transglutaminase-Related Signaling Pathways.

Qin XY, Fujii S, Shimizu A, Kagechika H, Kojima S.

J Nutr Sci Vitaminol (Tokyo). 2015;61(4):285-90. doi: 10.3177/jnsv.61.285.

9.

Transarterial chemoembolization versus hepatic resection in hepatocellular carcinoma treatment: a meta-analysis.

Tian X, Dai Y, Wang DQ, Zhang L, Sui CG, Meng FD, Jiang SY, Liu YP, Jiang YH.

Drug Des Devel Ther. 2015 Aug 10;9:4431-40. doi: 10.2147/DDDT.S86629. eCollection 2015. Review.

10.

Preventive effects of vitamin K on recurrent disease in patients with hepatocellular carcinoma arising from hepatitis C viral infection.

Kakizaki S, Sohara N, Sato K, Suzuki H, Yanagisawa M, Nakajima H, Takagi H, Naganuma A, Otsuka T, Takahashi H, Hamada T, Mori M.

J Gastroenterol Hepatol. 2007 Apr;22(4):518-22.

PMID:
17376044
11.

Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma.

Weis S, Franke A, Mössner J, Jakobsen JC, Schoppmeyer K.

Cochrane Database Syst Rev. 2013 Dec 19;(12):CD003046. doi: 10.1002/14651858.CD003046.pub3. Review.

PMID:
24357457
12.

[Hepatocellular carcinoma and vitamin K2].

Mizuta T, Ozaki I.

Clin Calcium. 2015 Nov;25(11):1645-51. doi: CliCa151116451651. Japanese.

PMID:
26503869
14.

Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection.

Chen LT, Chen MF, Li LA, Lee PH, Jeng LB, Lin DY, Wu CC, Mok KT, Chen CL, Lee WC, Chau GY, Chen YS, Lui WY, Hsiao CF, Whang-Peng J, Chen PJ; Disease Committee of Adjuvant Therapy for Postoperative Hepatocellular Carcinoma, Taiwan Cooperative Oncology Group, National Health Research Institutes, Zhunan, Taiwan.

Ann Surg. 2012 Jan;255(1):8-17. doi: 10.1097/SLA.0b013e3182363ff9.

PMID:
22104564
15.

Effect of vitamin K2 on the recurrence of hepatocellular carcinoma.

Yoshida H, Shiratori Y, Kudo M, Shiina S, Mizuta T, Kojiro M, Yamamoto K, Koike Y, Saito K, Koyanagi N, Kawabe T, Kawazoe S, Kobashi H, Kasugai H, Osaki Y, Araki Y, Izumi N, Oka H, Tsuji K, Toyota J, Seki T, Osawa T, Masaki N, Ichinose M, Seike M, Ishikawa A, Ueno Y, Tagawa K, Kuromatsu R, Sakisaka S, Ikeda H, Kuroda H, Kokuryu H, Yamashita T, Sakaida I, Katamoto T, Kikuchi K, Nomoto M, Omata M.

Hepatology. 2011 Aug;54(2):532-40. doi: 10.1002/hep.24430. Epub 2011 Jun 26.

PMID:
21574174
16.

Percutaneous ablation therapy versus surgical resection in the treatment for early-stage hepatocellular carcinoma: a meta-analysis of 21,494 patients.

Ni JY, Xu LF, Sun HL, Zhou JX, Chen YT, Luo JH.

J Cancer Res Clin Oncol. 2013 Dec;139(12):2021-33. doi: 10.1007/s00432-013-1530-1. Epub 2013 Sep 26.

PMID:
24072235
17.

Systematic review and meta-analysis of adjuvant i(131) lipiodol after excision of hepatocellular carcinoma.

Furtado R, Crawford M, Sandroussi C.

Ann Surg Oncol. 2014 Aug;21(8):2700-7. doi: 10.1245/s10434-014-3511-2. Epub 2014 Apr 18. Review.

PMID:
24743904
18.

Adjuvant chemotherapy for patients with primary hepatocellular carcinoma: a meta-analysis.

Zheng Z, Liang W, Wang D, Schroder PM, Ju W, Wu L, Zheng Z, Shang Y, Guo Z, He X.

Int J Cancer. 2015 Mar 15;136(6):E751-9. doi: 10.1002/ijc.29203. Epub 2014 Sep 19.

19.

Meta-analysis of laparoscopic vs open liver resection for hepatocellular carcinoma.

Xiong JJ, Altaf K, Javed MA, Huang W, Mukherjee R, Mai G, Sutton R, Liu XB, Hu WM.

World J Gastroenterol. 2012 Dec 7;18(45):6657-68. doi: 10.3748/wjg.v18.i45.6657.

20.

Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial.

Xia Y, Qiu Y, Li J, Shi L, Wang K, Xi T, Shen F, Yan Z, Wu M.

Ann Surg Oncol. 2010 Dec;17(12):3137-44. doi: 10.1245/s10434-010-1148-3. Epub 2010 Jul 3.

PMID:
20602260

Supplemental Content

Support Center